Daiichi Sankyo Company, Limited (TYO:4568)
2,770.00
-35.00 (-1.25%)
Aug 13, 2026, 3:30 PM JST
Daiichi Sankyo Company Revenue
Daiichi Sankyo Company had revenue of 574.74B JPY in the quarter ending June 30, 2026, with 21.10% growth. This brings the company's revenue in the last twelve months to 2.22T, up 15.51% year-over-year. In the fiscal year ending March 31, 2026, Daiichi Sankyo Company had annual revenue of 2.12T with 12.55% growth.
Revenue (ttm)
2.22T
Revenue Growth
+15.51%
P/S Ratio
2.27
Revenue / Employee
110.22M
Employees
20,171
Market Cap
5.04T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 2.12T | 236.79B | 12.55% |
| Mar 31, 2025 | 1.89T | 284.57B | 17.77% |
| Mar 31, 2024 | 1.60T | 323.21B | 25.28% |
| Mar 31, 2023 | 1.28T | 233.59B | 22.36% |
| Mar 31, 2022 | 1.04T | 82.38B | 8.56% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Otsuka Holdings | 2.62T |
| Astellas Pharma | 2.27T |
| Chugai Pharmaceutical | 1.34T |
| Kyowa Kirin | 529.80B |
| Ono Pharmaceutical | 504.41B |
| Santen Pharmaceutical | 291.84B |
| JCR Pharmaceuticals | 41.45B |
| Perseus Proteomics | 135.00M |
Daiichi Sankyo Company News
- 3 days ago - Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China - PRNewsWire
- 13 days ago - Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results - Business Wire
- 13 days ago - Daiichi Sankyo Company Earnings Call Transcript: Q1 2027 - Transcripts
- 13 days ago - Daiichi Sankyo Company Quarterly report: Q1 2027 - Filings
- 13 days ago - Daiichi Sankyo Company Slides: Q1 2027 - Filings
- 5 weeks ago - AstraZeneca, Daiichi near UK pricing deal for breast cancer drug, Bloomberg News reports - Reuters
- 2 months ago - Daiichi Sankyo Showcases Progress Across Industry-Leading Oncology Portfolio with Latest Research Updates at ASCO - Business Wire
- 2 months ago - Daiichi Sankyo Europe Reaffirms Commitment to Patient-Centred Care with Extensive Data Showcase at EAS Congress 2026 - Business Wire